168 related articles for article (PubMed ID: 12138344)
1. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.
Engelson ES; Glesby MJ; Mendez D; Albu JB; Wang J; Heymsfield SB; Kotler DP
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):379-91. PubMed ID: 12138344
[TBL] [Abstract][Full Text] [Related]
2. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents.
Viganò A; Mora S; Manzoni P; Schneider L; Beretta S; Molinaro M; di Natale B; Brambilla P
J Clin Endocrinol Metab; 2005 Jul; 90(7):4075-80. PubMed ID: 15840750
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of a growth hormone-releasing factor in patients with HIV.
Falutz J; Allas S; Blot K; Potvin D; Kotler D; Somero M; Berger D; Brown S; Richmond G; Fessel J; Turner R; Grinspoon S
N Engl J Med; 2007 Dec; 357(23):2359-70. PubMed ID: 18057338
[TBL] [Abstract][Full Text] [Related]
4. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism.
Hansen BR; Haugaard SB; Jensen FK; Jensen JE; Andresen L; Iversen J; Andersen O
HIV Med; 2010 Apr; 11(4):266-75. PubMed ID: 20002779
[TBL] [Abstract][Full Text] [Related]
5. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
[TBL] [Abstract][Full Text] [Related]
6. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
Glesby MJ; Albu J; Chiu YL; Ham K; Engelson E; He Q; Muthukrishnan V; Ginsberg HN; Donovan D; Ernst J; Lesser M; Kotler DP
PLoS One; 2013; 8(4):e61160. PubMed ID: 23593417
[TBL] [Abstract][Full Text] [Related]
8. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.
Rietschel P; Hadigan C; Corcoran C; Stanley T; Neubauer G; Gertner J; Grinspoon S
J Clin Endocrinol Metab; 2001 Feb; 86(2):504-10. PubMed ID: 11158000
[TBL] [Abstract][Full Text] [Related]
9. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.
Mulligan K; Khatami H; Schwarz JM; Sakkas GK; DePaoli AM; Tai VW; Wen MJ; Lee GA; Grunfeld C; Schambelan M
J Clin Endocrinol Metab; 2009 Apr; 94(4):1137-44. PubMed ID: 19174500
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.
Johannsson G; Mårin P; Lönn L; Ottosson M; Stenlöf K; Björntorp P; Sjöström L; Bengtsson BA
J Clin Endocrinol Metab; 1997 Mar; 82(3):727-34. PubMed ID: 9062473
[TBL] [Abstract][Full Text] [Related]
11. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
Nass R; Pezzoli SS; Oliveri MC; Patrie JT; Harrell FE; Clasey JL; Heymsfield SB; Bach MA; Vance ML; Thorner MO
Ann Intern Med; 2008 Nov; 149(9):601-11. PubMed ID: 18981485
[TBL] [Abstract][Full Text] [Related]
12. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.
Lo J; You SM; Canavan B; Liebau J; Beltrani G; Koutkia P; Hemphill L; Lee H; Grinspoon S
JAMA; 2008 Aug; 300(5):509-19. PubMed ID: 18677023
[TBL] [Abstract][Full Text] [Related]
13. A randomized, open-label study to compare the effects of two different doses of recombinant human growth hormone on fat reduction and fasting metabolic parameters in HIV-1-infected patients with lipodystrophy.
Bickel M; Zangos S; Jacobi V; Lutz T; Knecht G; Goebel F; Staszewski S; Klauke S
HIV Med; 2006 Sep; 7(6):397-403. PubMed ID: 16903985
[TBL] [Abstract][Full Text] [Related]
14. GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study.
Luzi L; Meneghini E; Oggionni S; Tambussi G; Piceni-Sereni L; Lazzarin A
Eur J Endocrinol; 2005 Dec; 153(6):781-9. PubMed ID: 16322383
[TBL] [Abstract][Full Text] [Related]
15. Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance.
Rao MN; Mulligan K; Tai V; Wen MJ; Dyachenko A; Weinberg M; Li X; Lang T; Grunfeld C; Schwarz JM; Schambelan M
J Clin Endocrinol Metab; 2010 Sep; 95(9):4361-6. PubMed ID: 20610601
[TBL] [Abstract][Full Text] [Related]
16. Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.
Leung V; Chiu YL; Kotler DP; Albu J; Zhu YS; Ham K; Engelson ES; Hammad H; Christos P; Donovan DS; Ginsberg HN; Glesby MJ
HIV Clin Trials; 2016 Mar; 17(2):55-62. PubMed ID: 27077672
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.
Sivakumar T; Mechanic O; Fehmie DA; Paul B
HIV Med; 2011 Sep; 12(8):453-62. PubMed ID: 21265979
[TBL] [Abstract][Full Text] [Related]
18. The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study.
Lo JC; Mulligan K; Noor MA; Lee GA; Schwarz JM; Grunfeld C; Schambelan M
Clin Infect Dis; 2004 Sep; 39(5):732-5. PubMed ID: 15356790
[TBL] [Abstract][Full Text] [Related]
19. Psoas muscle attenuation measurement with computed tomography indicates intramuscular fat accumulation in patients with the HIV-lipodystrophy syndrome.
Torriani M; Hadigan C; Jensen ME; Grinspoon S
J Appl Physiol (1985); 2003 Sep; 95(3):1005-10. PubMed ID: 12766180
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment.
Storer TW; Woodhouse LJ; Sattler F; Singh AB; Schroeder ET; Beck K; Padero M; Mac P; Yarasheski KE; Geurts P; Willemsen A; Harms MK; Bhasin S
J Clin Endocrinol Metab; 2005 Aug; 90(8):4474-82. PubMed ID: 15914526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
